View this email on our website CSE: MDM OTCQX: MRPHF FSE: 2M0 News Release May 21, 2018, Kelowna, BC Marapharm Ventures Inc. Closes Oversubscribed Financing for $4.5 million Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) (“Marapharm” or the “Company”) is pleased to announce that the non-brokered private placement unit offering announced in a news release on May 17, 2018, for gross proceeds of $4,000,000. has closed oversubscribed for total gross proceeds of $4,500,000.



The non-brokered private placement of 7,500,000 Units (“Units”) at CDN $0.60 per Unit (the “Unit Offering”), the Unit consists of one common share of the Company (a "Common Share") and one-half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each warrant entitles the holder thereof to purchase one Common Share of the Company at an exercise price of $0.70 for a period of 12 months from the date of issuance of the warrant.



Pursuant to the terms of the warrants, the expiry date of the warrants may be accelerated should the closing price at which the common shares trade exceeds $0.85 for five consecutive trading days. Any warrants which remain unexercised after the accelerated expiry date will be cancelled.



The net proceeds raised from the Unit Offering are intended to be used for (i) further development of the Company’s Las Vegas project (ii) further development of the Company’s project in Washington State (iii) further development of the Company’s projects in California and general corporate purposes. The common shares and warrants issued pursuant to the non-brokered offering are subject to a four month hold period. No finder's fees will be paid in connection with this non-brokered offering.

“We are weeks away from entering production at our newly built facilities in Nevada. 2018 will be the first revenue producing year for the Company, we are passionate about our future and excited to achieve these significant milestones.” Linda Sampson, CEO. For German Translations, visit www.marapharm.com/news

ABOUT MARAPHARM VENTURES INC. www.marapharm.com

Marapharm is a publicly traded company primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide.

FOR FURTHER INFORMATION: www.marapharm.com

Linda Sampson, CEO

Telephone: 778-583-4476

Email info@marapharm.com

SOCIAL MEDIA: Facebook: /marapharm

Twitter: /marapharm

WebTV: marapharm.tv

STOCK EXCHANGES: Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.

MARIJUANA INDUSTRY INVOLVEMENT: Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.



Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm's ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm's business is conducted in a manner consistent with state law and is in compliance with licensing requirements.



Copies of licenses are posted on Marapharm's website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.

FORWARD - LOOKING STATEMENTS: Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.